Lahita RGSex steroids and the rheumatic diseases. Arthritis Rheum1985; 28: 121-6.
2.
Mund A., Swison J., Rothfield J.Effect of pregnancy on the course of SLE. JAMA1963; 183: 917-70.
3.
Asherson RA, Harris EN, Hughes Grv.Complications of oral contraceptives and antiphospholipid antibodies . Arthritis Rheum1988; 31: 273-376.
4.
Cohen Jhm, Daniel L., Cordier G., Saez S., Reveillard J-P.Sex steroid receptors in peripheral T-cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive T cells. J Immunol1983; 131: 2767-71.
5.
Larocca LM, Piantelli M., Leone G. et al. Type II oestrogen binding sites in acute lymphoid and myeloid leukemias: growth inhibitory effect of oestrogen and flavenoids. Br J Haematol1990; 75: 489-95.
6.
Melo N., Hobday C., Dowsett M. et al. Oestrogen receptor analysis in B-cell chronic lymphocytic leukemia: correlation of biochemical and immunocytochemical methods. Leukemia Res1990; 14: 949-52.
7.
Lahita RGEstrogen metabolism in SLE patients and family members. Arthritis Rheum1982; 25: 843-6.
8.
Carlstein H. , Tarkowski A., Holmdahl R., Nillson LAOestrogen is a potent disease accelerator in SLE-prone MRL/MP-lpr/lpr mice. Clin Exp Immunol1990; 80: 467-73.
9.
Masse R., Yauinou P., Dorval J-C., Clides J.Reversal of lupus erythematosus-like disease with danazol. Lancet1980; ii: 651.
10.
Morley KD, Parke A., Hughes Grv.Systemic lupus erythematosus: two patients treated with danazol. Br Med J284: 1431-2.
11.
Sturgess AD , Evans Dtp, Mackay IR, Riglar A.Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus . J Clin Lab Immunol1984; 13: 11-14.
12.
Greenstein BD, Bridges E de F., Fitzpatrick Fta.Aromatase inhibitors regenerate the thymus in aging male rats. Int J Immunopharmacol1992; 14: 541-53.
13.
Greenstein BD, Dhaher YY, Bridges E de F al. Effects of an aromatase inhibitor on thymus and kidney and on oestrogen receptors in female MRL/MP-lpr/lpr mice. Lupus1993; 2: 221-5.
14.
Theofilopoulos AN, Dixon FJMurine models of SLE. Adv Immunol1985; 37: 269-390.
15.
Dowsett M., Goss PE, Powles TJ et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route . Cancer Res47: 1957-61.
16.
Santen RJ, Demers LM, Adlercreutz H. et al. Inhibition of aromatase with CGS 16949A in postmenopausal women . J Clin Endocrinol Metab1989; 68: 99-106.
17.
Lahita RG, Cheng CY, Monder C., Bardin C.Wayne. Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after treatment with 19-nortestosterone in men and lack of improvement in women. J Rheumatol1992; 19: 547-55.
